• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Dummer R.pdf
    Size:
    486.5Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Dummer, R.
    Long, G. V.
    Robert, C.
    Tawbi, H. A.
    Flaherty, K. T.
    Ascierto, P. A.
    Nathan, P. D.
    Rutkowski, P.
    Leonov, O.
    Dutriaux, C.
    Mandalà, M.
    Lorigan, P.
    Ferrucci, P. F.
    Grob, J. J.
    Meyer, N.
    Gogas, H.
    Stroyakovskiy, D.
    Arance, A.
    Brase, J. C.
    Green, S.
    Haas, T.
    Masood, A.
    Gasal, E.
    Ribas, A.
    Schadendorf, D.
    Show allShow less
    Affiliation
    University Hospital Zürich Skin Cancer Center, Zürich, Switzerland. Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia. Gustave Roussy, Villejuif, and Paris-Saclay University, Orsay, France. The University of Texas MD Anderson Cancer Center, Houston, TX. Dana-Farber Cancer Institute/Harvard Medical School and Massachusetts General Hospital, Boston, MA. Istituto Nazionale Tumori, IRCCS, Fondazione 'G. Pascale,' Naples, Italy. Mount Vernon Cancer Centre, Northwood, United Kingdom. Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland. Clinical Oncological Dispensary, Omsk, Russia. Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, Bordeaux, France. Unit of Medical Oncology, University of Perugia, Perugia, Italy. Unit of Medical Oncology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy. University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom. Department of Experimental Oncology, European Institute of Oncology, IRCCS, Milan, Italy. Timone Hospital AP-HM and Aix-Marseille University, Marseille, France. Université Toulouse III-Paul Sabatier, Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1037-CRCT, Toulouse, France. Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece. Moscow City Oncology Hospital, Moscow, Russia. Hospital Clinic of Barcelona, Barcelona, Spain. Novartis Pharma AG, Basel, Switzerland. Novartis Pharmaceuticals Corporation, East Hanover, NJ. Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA. University Hospital Essen, Essen, and German Cancer Consortium, Heidelberg, Germany.
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    PURPOSE Preclinical data suggest the combination of an anti–programmed death receptor 1 antibody plus dabrafenib and trametinib to have superior antitumor activity compared with dabrafenib plus trametinib alone. These observations are supported by translational evidence suggesting that immune checkpoint inhibitors plus targeted therapy may improve treatment outcomes in patients with BRAF V600–mutant metastatic melanoma. COMBI-i is a phase III trial evaluating spartalizumab, an anti–programmed death receptor 1 antibody, in combination with dabrafenib and trametinib (sparta-DabTram), versus placebo plus dabrafenib and trametinib (placebo-DabTram) in patients with BRAF V600–mutant unresectable or metastatic melanoma. METHODS Patients received spartalizumab 400 mg intravenously every 4 weeks plus dabrafenib 150 mg orally twice daily and trametinib 2 mg orally once daily or placebo-DabTram. Participants were age $ 18 years with unresectable or metastatic BRAF V600–mutant melanoma. The primary end point was investigator-assessed progression-free survival. Overall survival was a key secondary end point (ClinicalTrials.gov identifier: NCT02967692). RESULTS At data cutoff (July 1, 2020), the median progression-free survival was 16.2 months (95% CI, 12.7 to 23.9 months) in the sparta-DabTram arm versus 12.0 months (95% CI, 10.2 to 15.4 months) in the placeboDabTram arm (hazard ratio, 0.82 [95% CI, 0.66 to 1.03]; P 5 .042 [one-sided; nonsignificant]). The objective response rates were 69% (183 of 267 patients) versus 64% (170 of 265 patients), respectively. Grade $ 3 treatment-related adverse events occurred in 55% (146 of 267) of patients in the sparta-DabTram arm and 33% (88 of 264) in the placebo-DabTram arm. CONCLUSION The study did not meet its primary end point; broad first-line use of sparta-DabTram is not supported by these results. Further biomarker-driven investigation may identify patient subpopulations who could benefit from checkpoint inhibitor plus targeted therapy combinations.
    Citation
    Dummer R, Long GV, Robert C, Tawbi HA, Flaherty KT, Ascierto PA, et al. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022.
    Journal
    Journal of Clinical Oncology
    URI
    http://hdl.handle.net/10541/625077
    DOI
    10.1200/jco.21.01601
    PubMed ID
    35030011
    Additional Links
    https://dx.doi.org/10.1200/jco.21.01601
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1200/jco.21.01601
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i).
    • Authors: Tawbi HA, Robert C, Brase JC, Gusenleitner D, Gasal E, Garrett J, Savchenko A, Görgün G, Flaherty KT, Ribas A, Dummer R, Schadendorf D, Long GV, Nathan PD, Ascierto PA
    • Issue date: 2022 Jun
    • Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
    • Authors: Dummer R, Lebbé C, Atkinson V, Mandalà M, Nathan PD, Arance A, Richtig E, Yamazaki N, Robert C, Schadendorf D, Tawbi HA, Ascierto PA, Ribas A, Flaherty KT, Pakhle N, Campbell CD, Gusenleitner D, Masood A, Brase JC, Gasal E, Long GV
    • Issue date: 2020 Oct
    • Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF(V600)-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.
    • Authors: Dummer R, Brase JC, Garrett J, Campbell CD, Gasal E, Squires M, Gusenleitner D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Flaherty K, Larkin J, Robert C, Kefford R, Kirkwood JM, Hauschild A, Schadendorf D, Long GV
    • Issue date: 2020 Mar
    • Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.
    • Authors: Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Long GV
    • Issue date: 2018 Dec 10
    • Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
    • Authors: Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ
    • Issue date: 2017 Jul 1
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.